Efficacy and safety of Yangxinshi tablet for chronic heart failure: A systematic review and meta-analysis

doi:10.12998/wjcc.v12.i13.2218

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (380)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

HTML

207

Figures (1-9)

Tables (1-2)

Sum=325

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=41

May 6, 2024 (publication date) through May 8, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. May 6, 2024; 12(13): 2218-2230
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2218

Efficacy and safety of Yangxinshi tablet for chronic heart failure: A systematic review and meta-analysis

Sheng-Hua Lu, Yun-Feng Yu, Si-Si Dai, Ya-Qi Hu, Jian-He Liu

Sheng-Hua Lu, Yun-Feng Yu, Si-Si Dai, Ya-Qi Hu, Jian-He Liu, The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410007, Hunan Province, China

Sheng-Hua Lu, Jian-He Liu, Branch of National Clinical Research Center for Chinese Medicine Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, Hunan Province, China

Co-first authors: Sheng-Hua Lu and Yun-Feng Yu.

Author contributions: Lu SH acquisition of data, analysis and interpretation of data, drafting the article, final approval; Yu YF acquisition of data, analysis and interpretation of data, drafting the article, final approval; Dai SS interpretation of data, revising the article, final approval; Hu YQ interpretation of data, revising the article, final approval; Liu JH conception and design of the study, critical revision, final approval. All authors seriously revised and approved the final manuscript.

Supported by Hunan Provincial Chinese Medicine Research Program Commissioned Key Projects, No. D2023005.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jian-He Liu, MD, PhD, Professor, The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, No. 95 Shaoshan Middle Road, Yuhua District, Changsha 410007, Hunan Province, China. ljhtcm1@163.com

Received: February 2, 2024
Revised: March 10, 2024
Accepted: March 29, 2024
Published online: May 6, 2024

Core Tip

Core Tip: Chronic heart failure (CHF) represents a severe manifestation and late-stage complication of various heart diseases. This study aims to conduct a systematic evaluation of the efficacy and safety of Yangxinshi tablet (YXST) in the treating CHF through meta-analysis. The results indicate that YXST effectively improved clinical symptoms and cardiac function in patients with CHF while maintaining a favorable safety profile, suggesting its potential as a therapeutic strategy for CHF.